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Introduction
Richard Feynman, recipient of the 1965 Nobel Prize in 
Physics, once famously stated: ‘If we were to name the 
most powerful assumption of all, which leads one on and 
on in an attempt to understand life, it is that all things are 
made of atoms, and that everything that living things do 
can be understood in terms of the jigglings and wigglings 
of atoms.’ Much of the biophysics of the last 50 years has 
been dedicated to better understanding the nature of this 
atomic jiggling and wiggling. The quantum-mechanical 
laws  governing  motions  in  the  microscopic  world  are 
surprisingly foreign to those familiar with macroscopic 
dynamics.  Motions  are  governed  not  by  deterministic 
laws,  but  by  probability  functions;  chemical  bonds  are 
formed  not  mechanically,  but  by  shifting  clouds  of 
electrons that are simultaneously waves and particles. As 
Feynman  eloquently  put  it,  this  is  ‘nature  as  she  is  - 
absurd’ [1].
Understanding  these  absurd  molecular  motions  is 
undoubtedly germane to drug discovery. The initial ‘lock-
and-key’ theory of ligand binding [2], in which a frozen, 
motionless receptor was thought to accommodate a small 
molecule  without  undergoing  any  conformational  re-
arrange  ments,  has  been  largely  abandoned  in  favor  of 
binding models that account not only for conformational 
changes, but also for the random jiggling of receptors and 
ligands [3-7].
The mollusk acetylcholine binding protein (AChBP), a 
structural  and  functional  surrogate  of  the  human 
nicotinic  acetylcholine  receptor  (AChR)  ligand-binding 
domain [8-11], is one of countless examples that illustrate 
the importance of accounting for these atomistic motions 
(Figure 1). In crystallographic structures of small-mole-
cule AChR agonists bound to AChBP, a key loop (loop C) 
partially closes around the ligand (Figure 1a,c). In con-
trast,  crystal  structures  of  large  AChR  antagonists  like 
snake  α-neurotoxins  bound  to  AChBP  reveal  that  this 
same loop is displaced by as much as 10 Å, producing an 
active site that is far more open (Figure 1b,c) [12]. Bourne 
et al. [12] proposed that the unbound AChBP and AChR 
are  highly  dynamic  proteins  that,  in  the  absence  of  a 
ligand,  sample  many  conformational  states,  both  open 
and closed, that are selectively stabilized by the binding 
of agonists and antagonists. Any one of these binding-
pocket  conformations  may  be  druggable  and  therefore 
pharmacologically  relevant.  If  this  general  model  of 
ligand binding is correct, the implications for structure-
based drug design are profound, as the same principle of 
binding likely applies to many other systems as well.
Molecular dynamics simulations
While  crystallographic  studies  like  these  convincingly 
demonstrate the important role protein flexibility plays in 
ligand binding, the expense and extensive labor required 
to generate them have led many to seek computational 
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nately, the calculations required to describe the absurd 
quantum-mechanical motions and chemical reactions of 
large  molecular  systems  are  often  too  complex  and 
computationally  intensive  for  even  the  best  super-
computers. Molecular dynamics (MD) simulations, first 
developed in the late 1970s [13], seek to overcome this 
limitation  by  using  simple  approximations  based  on 
Newtonian  physics  to  simulate  atomic  motions,  thus 
reducing  the  computational  complexity.  The  general 
process of approximation used is outlined in Figure 2. 
First,  a  computer  model  of  the  molecular  system  is 
prepared  from  nuclear  magnetic  resonance  (NMR), 
crystallo  graphic, or homology-modeling data. The forces 
acting on each of the system atoms are then estimated 
from  an  equation  like  that  shown  in  Figure  3  [14].  In 
brief,  forces  arising  from  interactions  between  bonded 
and non-bonded atoms contribute. Chemical bonds and 
atomic angles are modeled using simple virtual springs, 
and dihedral angles (that is, rotations about a bond) are 
modeled using a sinusoidal function that approximates 
the  energy  differences  between  eclipsed  and  staggered 
conformations. Non-bonded forces arise due to van der 
Waals interactions, modeled using the Lennard-Jones 6-
12 potential [15], and charged (electrostatic) interactions, 
modeled  using  Coulomb’s  law.  For  a  more  in-depth 
review  describing  how  the  equations  describing  these 
interactions are parameterized, see [14].
In order to reproduce the actual behavior of real mole-
cules in motion, the energy terms described above are 
parameterized  to  fit  quantum-mechanical  calculations 
and experimental (for example, spectroscopic) data. This 
parameterization includes identifying the ideal stiffness 
and lengths of the springs that describe chemical bonding 
and atomic angles, determining the best partial atomic 
charges  used  for  calculating  electrostatic-interaction 
energies,  identifying  the  proper  van  der  Waals  atomic 
radii, and so on. Collectively, these parameters are called 
a ‘force field’ because they describe the contributions of 
the various atomic forces that govern molecular dynamics. 
Figure 1. The different conformations of the acetylcholine 
binding protein from Lymnaea stagnalis. Portions of the protein 
have been removed to facilitate visualization. (a) The protein in a 
closed conformation with nicotine bound (PDB ID: 1UW6), shown in 
blue. (b) The protein in an open conformation (PDB ID: 1YI5) with the 
same nicotine conformation superimposed on the structure, shown 
in pink. (c) Ribbon representations of the two conformations.
Figure 2. A schematic showing how a molecular dynamics 
simulation is performed. First, a computer model of the receptor-
ligand system is prepared. An equation like that shown in Figure 3 
is used to estimate the forces acting on each of the system atoms. 
The positions of the atoms are moved according to Newton’s laws of 
motion. The simulation time is advanced, and the process is repeated 
many times. This figure was adapted from a version originally created 
by Kai Nordlund.
Initial atomic model
Calculate molecular forces acting on each atom
Move each atom according to those forces
Advance simulation time by 1 or 2 fs
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dynamics  simulations,  including  AMBER  [14,16], 
CHARMM [17], and GROMOS [18]. These differ princi-
pally in the way they are parameterized but generally give 
similar results.
Once the forces acting on each of the system atoms 
have  been  calculated,  the  positions  of  these  atoms  are 
moved according to Newton’s laws of motion. The simu-
la  tion  time  is  then  advanced,  often  by  only  1  or 
2 quadrillionths of a second, and the process is repeated, 
typically millions of times. Because so many calculations 
are  required,  molecular  dynamics  simulations  are 
typically  performed  on  computer  clusters  or  super-
computers using dozens if not hundreds of processors in 
parallel. Many of the most popular simulation software 
packages,  which  often  bear  the  same  names  as  their 
default force fields (for example AMBER [19], CHARMM 
[17],  and  NAMD  [20,21]),  are  compatible  with  the 
Message Passing Interface (MPI), a system of computer-
to-computer messaging that greatly facilitates the execu-
tion  of  complex  tasks  by  one  software  application  on 
multiple processors operating simultaneously.
While  the  utility  of  molecular  dynamics  simulations 
should not be overstated, a number of studies comparing 
these simulations with experimental data have been used 
to validate the computational technique [22]. NMR data 
are particularly useful, as the many receptor and ligand 
conformations  sampled  by  molecular  dynamics 
simulations can be used to predict NMR measurements 
like spin relaxation, permitting direct comparison between 
experimental  and  theoretical  techniques.  Indeed,  a 
number of studies have shown good agreement between 
computational and experimental measurements of macro-
molecular dynamics [23-26].
Molecular dynamics simulations: current limitations
These successes aside, the utility of molecular dynamics 
simulations  is  still  limited  by  two  principal  challenges 
[27]: the force fields used require further refinement, and 
high  computational  demands  prohibit  routine  simula-
tions  greater  than  a  microsecond  in  length,  leading  in 
many cases to an inadequate sampling of conformational 
states.  As  an  example  of  these  high  computational 
demands, consider that a one-microsecond simulation of 
a  relatively  small  system  (approximately  25,000  atoms) 
running  on  24  processors  takes  several  months  to 
complete.
Aside  from  challenges  related  to  the  high  compu-
tational  demands  of  these  simulations,  the  force  fields 
used are also approximations of the quantum-mechanical 
reality  that  reigns  in  the  atomic  regime.  While  simu-
lations can accurately predict many important molecular 
motions, these simulations are poorly suited to systems 
where quantum effects are important, for example, when 
transition metal atoms are involved in binding.
To  overcome  this  challenge,  some  researchers  have 
introduced quantum mechanical calculations into classic 
molecular-dynamics  force  fields;  the  motions  and 
reactions of enzymatic active sites or other limited areas 
of  interest  are  simulated  according  to  the  laws  of 
quantum mechanics, and the motions of the larger sys-
tem are approximated using molecular dynamics. While 
far from the computationally intractable ‘ideal’ of using 
quantum mechanics to describe the entire system, this 
hybrid technique has nevertheless been used successfully 
to study a number of systems. For example, in one recent 
simulation of Desulfovibrio desulfuricans and Clostridium 
pasteurianum  [Fe-Fe]  hydrogenases,  a  ‘QM  [quantum 
mechanical]  region’  was  defined  encompassing  a 
Figure 3. An example of an equation used to approximate the atomic forces that govern molecular movement. The atomic forces that 
govern molecular movement can be divided into those caused by interactions between atoms that are chemically bonded to one another and 
those caused by interactions between atoms that are not bonded. Chemical bonds and atomic angles are modeled using simple springs, and 
dihedral angles (that is, rotations about a bond) are modeled using a sinusoidal function that approximates the energy differences between 
eclipsed and staggered conformations. Non-bonded forces arise due to van der Waals interactions, modeled using the Lennard-Jones potential, 
and charged (electrostatic) interactions, modeled using Coulomb’s law.
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cata  lytically important, and the remainder of the protein 
was simulated using classical molecular dynamics [28]. 
The simulations revealed an important proton transfer in 
the  QM  region,  a  bond-breaking  and  bond-formation 
event that could not have been modeled with a traditional 
force  field.  The  hypothesized  catalytic  mechanism  was 
subse  quently supported by experimental evidence.
Aside  from  bond  breaking  and  formation,  electronic 
polarization, caused by the flow of electrons from one 
atomic nucleus to another among groups of atoms that 
are chemically bonded, is another quantum-mechanical 
effect that, with few exceptions, is generally ignored. In 
classical molecular dynamics simulations, each atom is 
assigned  a  fixed  partial  charge  before  the  simulation 
begins. In reality, however, the electron clouds surround-
ing  atoms  are  constantly  shifting  according  to  their 
environments, so that the partial charges of atoms would 
be better represented as dynamic and responsive. Despite 
wide  agreement  on  the  importance  of  accounting  for 
electronic polarization, after 30 years of development a 
generally  accepted  polarizable  force  field  has  not  been 
forthcoming, and molecular dynamics simulations using 
those  force  fields  that  are  available  are  rare  [29]. 
Nevertheless,  a  number  of  polarizable  force  fields  are 
currently under development [30], and future implemen-
ta  tions may lead to improved accuracy.
In addition to neglecting quantum-mechanical effects, 
molecular dynamics studies are also limited by the short 
time  scales  typically  simulated.  To  reproduce  thermo-
dynamic properties and/or to fully elucidate all binding-
pocket  configurations  relevant  to  drug  design,  all  the 
possible  conformational  states  of  the  protein  must  be 
explored  by  the  simulation.  Unfortunately,  many  bio-
chemical  processes,  including  receptor  conformational 
shifts relevant to drug binding, occur on time scales that 
are much longer than those amenable to simulation. With 
some important exceptions [31], simulations are currently 
limited to at most millionths of a second; indeed, most 
simulations are measured in billionths of a second.
A number of solutions to this challenge have already 
seen limited use. For example, in accelerated molecular 
dynamics (aMD) [32,33], large energy barriers are artifi-
cially reduced. Though this process inevitably introduces 
some  artifacts,  it  does  allow  proteins  to  shift  between 
conformations  that  would  not  be  accessible  given  the 
time scales of conventional molecular dynamics. These 
novel conformations can then be further studied using 
classical molecular dynamics or other techniques.
Novel hardware has also been used to overcome the 
time-scale limitations of conventional molecular dynamics 
simulations. Many of the same calculations required for 
these  simulations  are  commonly  performed  by  video-
game and computer-graphics applications. Conse  quently, 
the same graphics-processing-units (GPUs) designed to 
speed up video games can be used to speed up molecular 
dynamics  simulations  as  well,  usually  by  an  order  of 
magnitude [34-36].
Not satisfied with merely adapting molecular-dynamics 
code  to  run  on  specialized  graphics  processors,  some 
engineers have designed new processors specifically for 
these simulations. The research group of DE Shaw is one 
notable  advocate  of  this  approach.  They  have  built  a 
supercomputer codenamed Anton capable of performing 
microseconds of simulation per day. With Anton, simula-
tions longer than one millisecond [31] have successfully 
captured protein folding and unfolding as well as drug-
binding events [37]. Shortcomings certainly still exist, but 
these and other future techniques will likely make great 
progress  towards  overcoming  current  limitations  on 
conformational sampling.
Molecular dynamics simulations and drug discovery
Weaknesses  in  current  force  fields  and  conformational 
sampling aside, molecular dynamics simulations and the 
insights they offer into protein motion often play impor-
tant roles in drug discovery. Just as a single photograph of 
a  runner  tells  little  about  her  stride,  a  single  protein 
conformation  tells  little  about  protein  dynamics.  The 
static models produced by NMR, X-ray crystallography, 
and  homology  modeling  provide  valuable  insights  into 
macromolecular  structure,  but  molecular  recognition 
and drug binding are very dynamic processes. When a 
small  molecule  like  a  drug  (for  example,  a  ligand) 
approaches its target (for example, a receptor) in solution, 
it encounters not a single, frozen structure, but rather a 
macromolecule in constant motion.
In some rare cases, protein motions are limited, and 
the ligand may fit into a fairly static binding pocket like a 
key fits into a lock [2]. More typically, the ligand may 
bind  and  stabilize  only  a  subset  of  the  many  confor-
mations  sampled  by  its  dynamic  receptor,  causing  the 
population of all possible conformations to shift towards 
those  that  can  best  accommodate  binding  [4-7].  Upon 
binding, the ligand may further induce conformational 
changes that are not typically sampled when the ligand is 
absent [38]. Regardless, receptor motions clearly play an 
essential  role  in  the  binding  of  most  small-molecule 
drugs. Several techniques have been developed to exploit 
the  information  about  these  motions  that  molecular 
dynamics simulations can provide.
Identifying cryptic and allosteric binding sites
NMR and X-ray crystallographic structures often reveal 
well  defined  binding  pockets  that  accommodate  endo-
genous  ligands;  however,  sometimes  the  models  pro-
duced by these experimental techniques obscure other 
potentially  druggable  sites.  As  these  sites  are  not 
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sometimes called cryptic binding sites.
Molecular dynamics simulations are excellent tools for 
identifying  such  sites  [39-41].  For  example,  in  2004 
Schames  et  al.  [39]  performed  a  molecular  dynamics 
simu  lation of HIV integrase, a drug target that had not 
seemed  amenable  to  structure-based  drug  design.  The 
simulations revealed a previously unidentified trench that 
was not evident from any of the available crystal struc-
tures.  X-ray  crystallography  later  demonstrated  that 
known inhibitors do in fact bind in this cryptic trench, as 
predicted. These results led to new experimental studies 
at  Merck  &  Co.  [42];  further  development  ultimately 
resulted in production of the highly effective antiretro-
viral drug raltegravir, the first US Food and Drug Admin-
is  tration-approved HIV integrase inhibitor.
Aside from cryptic binding sites, molecular dynamics 
simulations can also be used to identify druggable allo-
steric sites. In one recent study, Ivetac and McCammon 
[43] performed simulations of the human β1 (β1AR) and 
β2 (β2AR) adrenergic receptors. Multiple protein confor-
mations were extracted from these simulations, and the 
protein surface was computationally ‘flooded’ with small 
organic probes using FTMAP [44] to identify potential 
binding sites. Regions of the protein surface where the 
organic probes consistently congregated across multiple 
structures  were  then  identified  as  potential  allosteric 
sites. In all, five potential sites were identified, some of 
which  were  not  evident  in  any  of  the  existing  crystal 
structures.
Improving the computational identification of 
true small-molecule binders: the relaxed complex 
scheme
One common technique used to identify the precursors 
of potential drugs in silico is virtual screening. A docking 
program is used to predict the binding pose and energy 
of  a  small-molecule  model  within  a  selected  receptor 
binding  pocket.  Traditionally,  many  ligand  models, 
typically taken from a database of compounds that can be 
easily synthesized or commercially purchased, are docked 
into  a  single  static  receptor  structure,  often  obtained 
from NMR or X-ray crystallography. The best predicted 
ligands are subsequently tested experimentally to confirm 
binding.
Unfortunately, traditional docking relying on a single 
receptor structure is problematic. Some legitimate ligands 
may indeed bind to the single structure selected, but in 
reality most receptor binding pockets have many valid 
conformational  states,  any  one  of  which  may  be 
druggable. In a traditional virtual screen, true ligands are 
often  discarded  because  they  in  fact  bind  to  receptor 
conformations  that  differ  markedly  from  that  of  the 
single static structure chosen.
To better account for receptor flexibility, a new virtual-
screening protocol has been developed called the relaxed 
complex  scheme  (RCS)  [45,46].  Rather  than  docking 
many  compound  models  into  a  single  NMR  or  crystal 
structure, each potential ligand is docked into multiple 
protein conformations, typically extracted from a mole-
cu  lar  dynamics  simulation.  Thus,  each  ligand  is  asso-
ciated not with a single docking score but rather with a 
whole spectrum of scores. Ligands can be ranked by a 
number of spectrum characteristics, such as the average 
score over all receptors. Thus, the RCS effectively accounts 
for  the  many  receptor  conformations  sampled  by  the 
simulations; it has been used successfully to identify a 
number of protein inhibitors, including inhibitors of FKBP 
[47], HIV integrase [39], Trypanosoma brucei RNA edit-
ing ligase 1 [48,49], T. brucei GalE [50], T. brucei FPPS 
[51], and Mycobacterium tuberculosis dTDP-6-deoxy-L-
lyxo-4-hexulose [52]. In two of these projects, the identi-
fied inhibitors were effective not only against the target 
proteins, but against the whole-cell parasite [49,50].
While  these  successes  are  promising,  the  relaxed 
complex scheme certainly has its weaknesses. Aside from 
being based on molecular dynamics simulations that are 
themselves  subject  to  crude  force-field  approximations 
and  inadequate  conformational  sampling,  the  scheme 
relies  on  computer-docking  scoring  functions  that  of 
necessity  are  optimized  for  speed  at  the  expense  of 
accuracy.  In  order  to  facilitate  high-throughput  virtual 
screening,  these  scoring  functions  often  treat  subtle 
influences on binding energy like conformational entropy 
and  solvation  energy  only  superficially  [27,53],  thus 
sacrificing accuracy for the sake of greater speed.
Advanced free-energy calculations using molecular 
dynamics simulations
Though docking programs are optimized for speed rather 
than  accuracy,  more  accurate,  albeit  computationally 
intensive,  techniques  for  predicting  binding  affinity  do 
exist.  These  techniques,  which  include  thermodynamic 
integration [54], single-step perturbation [55], and free 
energy  perturbation  [56],  are  based  in  large  part  on 
molecular dynamics simulations.
Free energy is a state function, meaning that the free-
energy  difference  associated  with  a  given  event  like  a 
drug binding to its receptor is determined only by the 
energy prior to that event and the energy following it; 
while the path taken from the initial to the final state may 
influence receptor-ligand kinetics, it has no bearing on 
the  free  energy.  Perhaps  the  ligand  diffuses  slowly 
towards the active site and slips easily into the binding 
pocket.  Perhaps  the  protein  unfolds  entirely  and  then 
refolds around the ligand. Perhaps the ligand in solution 
is beamed to a starship in orbit, only to rematerialize in 
the active site a few seconds later. The mechanics do not 
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energy  in  solution  and  the  final  energy  following  the 
binding event.
With  some  notable  exceptions  [37],  simulating  a 
receptor-ligand system long enough to capture an entire 
binding event is not currently feasible. However, it is still 
possible  to  calculate  a  drug’s  binding  affinity  using  a 
technique called ‘alchemical transformation’ , first described 
in 1984 [57]. This transformation is not too different from 
the starship example given above. During the course of a 
molecular dynamics simulation, the electrostatic and van 
der Waals forces produced by ligand atoms are turned 
down  gradually  enough  to  avoid  undesirable  artifacts. 
Eventually, the ligand is no longer able to interact with 
the  protein  or  solvent.  For  all  practical  purposes,  the 
ligand  has  disappeared.  It  does  not  matter  that  this 
transformation is not at all physical; free energy is a state 
function, so the path from the initial to the final state, 
whether real or imaginary, is irrelevant.
It  is  not  clear,  however,  in  what  context  the  ligand 
should be figuratively annihilated in this way. Should a 
molecular  dynamics  simulation  be  run  in  which  the 
bound ligand vanishes? What about the ligand in solu-
tion?  To  address  these  questions,  alchemical  transfor-
mations are selected based on the thermodynamic cycle 
shown in Figure 4. As free energy is a state function that 
depends only on the energy of the initial and final states, 
a system that proceeds from one state around this free-
energy cycle only to return to the same initial state should 
have  no  change  in  total  free  energy  (that  is,  ΔGbind  + 
ΔGprotein  -  ΔG  -  ΔGwater  =  0).  We  note  that  ΔG  in  this 
equation  is  itself  zero,  since  the  ligand  is  entirely 
disappeared in both of the states shown in the bottom 
half of Figure 4, meaning the ligand cannot interact with 
the  water  solvent  or  the  protein  in  either  state.  Thus, 
ΔGbind + ΔGprotein - ΔGwater = 0, and, consequently, ΔGbind = 
ΔGwater - ΔGprotein. These equations demonstrate that it is 
possible to estimate a drug’s free energy of binding, an 
indirect measurement of drug potency, by running two 
simulations, one in which the receptor-bound ligand dis-
appears, and one in which the solvated ligand disappears.
A  similar  task,  calculating  relative  ligand  binding 
energies,  is  useful  during  drug  optimization  when  one 
wishes  to  determine  if  a  given  chemical  change  will 
improve the potency of a candidate ligand. In this case, 
rather than annihilating the entire ligand, one section of 
the ligand is gradually transformed. For example, a key 
carbon  atom  might  be  gradually  converted  into  an 
oxygen atom to see if the binding affinity is improved or 
diminished. These kinds of alchemical molecular dynamics 
simulations may provide medicinal chemists with useful 
insights that can guide further drug development.
A series of early fortuitous results that agreed remark-
ably well with experiments led many to an enthusiasm for 
molecular-dynamics-based  free-energy  calculations  in 
the  1980s  and  early  1990s  that  was  not  matched  in 
subsequent decades [27,58] as computational predictions 
fell  short  of  experimental  measurements.  However, 
steady  algorithmic  and  engineering  advances  in  recent 
years  have  led  to  renewed  attention.  The  successful 
applications of alchemical techniques in recent years are 
legion; accurate predictions have been obtained for ligand 
binding to the src SH2 domain [59], to a mutant T4 lyso-
zyme [60], to FKBP12 [61], to HIV reverse transcriptase 
[62], to trypsin [63], to a bacterial ribosome [64], and to 
estrogen receptor-α [65], among many others.
These successes aside, it is important not to oversell 
alchemical  techniques.  All  molecular-dynamics-based 
drug-discovery techniques would benefit from improved 
force  fields,  but  the  alchemical  techniques  are,  in 
addition, uniquely sensitive to inadequate conformational 
sampling [66]. When molecular dynamics simulations of 
insufficient  length  are  used  to  identify  cryptic  sites, 
allosteric  sites,  or  pharmacologically  relevant  binding-
pocket conformations for virtual-screening projects, the 
risk is that some suitable receptor conformations will be 
missed. The conformations that are identified, however, 
are still useful; the results of the simulation are therefore 
incomplete, but not necessarily wrong.
However, the alchemical techniques used to calculate 
free  energies  of  binding  are  far  more  dependent  on 
thorough conformational sampling than are RCS screens. 
If molecular dynamics simulations fail to sample system 
conformations  that  are  in  fact  sampled  ex  silico,  these 
conformations will not contribute to the total calculated 
energy, leading to an incorrect prediction of the binding 
affinity.  Molecular  dynamics  simulations  are  compu-
tation  ally demanding and often of necessity unacceptably 
short; insufficient conformational sampling is therefore a 
common problem that future algorithmic and hardware-
engineering  efforts  must  address.  It  is  largely  because 
accurate  predictions  often  require  lengthy  simulations 
that these alchemical techniques have not yet been widely 
adopted  by  the  pharmaceutical  industry,  despite  great 
interest [27].
Conclusions
In  this  review,  we  have  discussed  the  many  roles  that 
molecular  dynamics  simulations  can  play  in  drug  dis-
covery, including the identification of cryptic or allosteric 
binding  sites,  the  enhancement  of  traditional  virtual-
screening  methodologies,  and  the  direct  prediction  of 
ligand  binding  energies.  As  ligand  binding  and  the 
impor  tant  macromolecular  motions  associated  with  it 
are microscopic events that take place in mere millionths 
of a second, a complete understanding of the atomistic 
energetics and mechanics of binding is unattainable using 
current  experimental  techniques.  Molecular  dynamics 
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Page 6 of 9Figure 4. The thermodynamic cycle used for selecting alchemical transformations. Typically, one wishes to calculate the free energy of 
binding, ΔGbind, shown across the top. However, it is generally impractical to run a molecular dynamics simulation long enough to capture an entire 
binding event. Instead, a series of alchemical transformations are performed using molecular dynamics simulations. ΔGprotein is the change in free 
energy that occurs when a bound ligand is ‘annihilated’. ΔG is the change in free energy that occurs when an unbound ‘ghost’ ligand binds to the 
receptor; however, since a ghost ligand is not able to interact with any solvent or receptor atoms, this energy is always zero. Finally, ΔGwater is the 
change in free energy that occurs when an unbound ligand in solution is ‘annihilated’. A system that proceeds from one state around this free-
energy cycle only to return to the same initial state should have no change in total free energy; consequently, ΔGbind = ΔGwater - ΔGprotein.
∆Gbind
∆G = 0
∆Gwater ∆Gprotein
∆Gbind + ∆Gprotein – ∆G – ∆Gwater = 0
∆Gbind + ∆Gprotein – ∆Gwater = 0
∆Gbind = ∆Gwater – ∆Gprotein
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Page 7 of 9simulations  are  useful  for  filling  in  the  details  where 
experimental methods cannot.
With constant improvements in both computer power 
and algorithm design, the future of computer-aided drug 
design is promising; molecular dynamics simulations are 
likely  to  play  an  increasingly  important  role  in  the 
develop  ment of novel pharmacological therapeutics.
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